J Thorac Cardiovasc Surg 2011;142:477-478
© 2011 The American Association for Thoracic Surgery
Alice in wonderland of mediastinal lymph nodes
Hisato Takagi, MD, PhD,
Masafumi Matsui, MD,
Takuya Umemoto, MD, PhD
Department of Cardiothoracic Surgery, Shizuoka Medical Center, Shizuoka, Japan
|The first 20% of the full text of this article appears below.|
To the Editor:
We read with great interest the results of the American College of Surgery Oncology Group (ACOSOG) Z0030 trial,1 which was a randomized, multi-institutional, prospective trial of mediastinal lymph node dissection (MLND) versus sampling (MLNS) during pulmonary resection for patients with early-stage (N0 or nonhilar N1, T1, or T2) non–small cell lung cancer (NSCLC). At a median follow-up of 6.5 years, 44% died in the MLNS arm and 42% died in the MLND arm, and the median survival was 8.1 years in the MLNS group and 8.5 years in the MLND group (P = .25). Studies addressing the survival benefit of MLND, however, have been . . . [Full Text of this Article]
Reply to the Editor
- Gail Darling, Mark S. Allen, and Paul A. Decker
J. Thorac. Cardiovasc. Surg. 2011 142: 478-479.
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial
- Gail E. Darling, Mark S. Allen, Paul A. Decker, Karla Ballman, Richard A. Malthaner, Richard I. Inculet, David R. Jones, Robert J. McKenna, Rodney J. Landreneau, Valerie W. Rusch, and Joe B. Putnam, Jr.
J. Thorac. Cardiovasc. Surg. 2011 141: 662-670.
Copyright © 2011 by The American Association for Thoracic Surgery.